RMS13, NCT01871766: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy |
|
|
| Active, not recruiting | 2 | 98 | US | Vincristine, Oncovin®, Dactinomycin, Actinomycin-D, Cosmegen®, Cyclophosphamide, Cytoxan(R), Surgical Resection, Surgery, Radiation, Proton Beam Radiation, External Beam Radiation, Brachytherapy, Bevacizumab, rhuMab, VEGF, Avastin®, Sorafenib, Nexavar®, Myeloid Growth Factor, G-CSF, Filgrastim, Pegfilgrastim, Lymph Node Sampling, Irinotecan, Camptosar ®, Ifosfamide, Ifex ®, Etoposide, VP-16, Vepesid®, Etoposide Phosphate, Etopophos®, Doxorubicin, Adriamycin®, Dexrazoxane, Zinecard, ^1^1C-methionine, Contrast Media | St. Jude Children's Research Hospital | Rhabdomyosarcoma | 07/25 | 06/30 | | |
TINKS, NCT05634369: A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue |
|
|
| Recruiting | 1/2 | 50 | US | GEM/DOX + TGFBi expanded NK cells, Docetaxel, Dexamethasone, Pegfilgrastim, Gemcitabine | Nationwide Children's Hospital, National Pediatric Cancer Foundation | Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed | 12/26 | 12/27 | | |
| Completed | 1 | 12 | US | Cabozantinib, COMETRIQ™, Topotecan, Hycamtin®, Cyclophosphamide, Neosar®, Cytoxan®, Myeloid growth factor, Filgrastim, Pegfilgrastim | Dana-Farber Cancer Institute | Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma | 10/22 | 10/22 | | |
